During the corresponding time, Sanara Medtech Inc recorded a revenue increase by 13.03 % year on year, sequentially revenue grew by 4.7 %. While revenue at the Sanara Medtech Inc 's corporate clients
Sanara Medtech Inc's Comment on Sales, Marketing and Customers
The company serves multiple customer segments, including patients, surgeons, healthcare systems, and distributor partners. For patients, it provides solutions aimed at supporting natural healing and reducing complications. Surgeons receive clinically proven tools designed to address surgical challenges. Healthcare systems are supplied with evidence-based products intended to improve outcomes, reduce complications, control costs, and enhance care quality. Distributor partners are offered a broad portfolio of effective products to support surgeons and improve patient outcomes.
The company seeks to expand its geographic presence across the United States and strengthen its position in surgical markets. Its product portfolio strategy, "Prepare, Promote and Protect," includes products such as BIASURGE for procedure preparation; orthobiologic products including BiFORM, ACTIGEN, and ALLOCYTE Plus for tissue repair; and CellerateRX Surgical for wound protection. The company has partnered with Biomimetic Innovations Limited to commercialize new products, including OsStic BioAdhesive, expected in 2027, aimed at enhancing surgical site outcomes and providing improved value propositions compared to competitors.
Sanara Medtech Inc’s Comment on Sales, Marketing and Customers
The company serves multiple customer segments, including patients, surgeons, healthcare systems, and distributor partners. For patients, it provides solutions aimed at supporting natural healing and reducing complications. Surgeons receive clinically proven tools designed to address surgical challenges. Healthcare systems are supplied with evidence-based products intended to improve outcomes, reduce complications, control costs, and enhance care quality. Distributor partners are offered a broad portfolio of effective products to support surgeons and improve patient outcomes.
The company seeks to expand its geographic presence across the United States and strengthen its position in surgical markets. Its product portfolio strategy, "Prepare, Promote and Protect," includes products such as BIASURGE for procedure preparation; orthobiologic products including BiFORM, ACTIGEN, and ALLOCYTE Plus for tissue repair; and CellerateRX Surgical for wound protection. The company has partnered with Biomimetic Innovations Limited to commercialize new products, including OsStic BioAdhesive, expected in 2027, aimed at enhancing surgical site outcomes and providing improved value propositions compared to competitors.
Sources:
Sanara Medtech Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Sanara Medtech Inc’s corporate clients.
For your research, we’ve provided 9 tables on Sanara Medtech Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
178.36 %